Study summary

Rituximab did not beat standard treatment for EGPA

REOVAS trial · 105 people, randomized · Published July 2025, Annals of Internal Medicine

63.5%in remission at day 180 with rituximab, vs 60.4%

What was tested

Rituximab with steroids, against conventional treatment (steroids, with cyclophosphamide for severe disease), to induce remission in EGPA.

What they found

Remission at day 180 was 63.5% vs 60.4%, not significantly different.
Relapses and side effects were similar.

What it means

Unlike in GPA and MPA, rituximab is not clearly better for EGPA; anti-IL-5 drugs are preferred.

Ann Intern Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.